Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03342911 · OUTCOME

Number of Patients Who Achieved Major Pathologic Response (Defined as 10% or Less Residual Viable Tumor)

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery · Source last updated 2025-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of major response
Interval / dispersion
95% Confidence Interval
Time frame
Up to 26 months

What was measured

patients achieved the major pathologic response (i.e., \<10% viable tumor) or pathologic complete response

Analysis population: number of patients with Major response (Major or complete) was 72.73% (24/33) with a 95% Confidence Interval of 54.2% to 86.1%.

Groups in this outcome

Treatment (Nivolumab, Paclitaxel, Carboplatin)

Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV Carboplatin: Given IV Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Nivolumab, Paclitaxel, Carboplatin)33

Reported measurements

Source class 1
Values in percentage of major response · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Nivolumab, Paclitaxel, Carboplatin)72.73Not reported54.286.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        54.2
        upper Limit
        86.1
        value
        72.73
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
patients achieved the major pathologic response (i.e., \<10% viable tumor) or pathologic complete response
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV Carboplatin: Given IV Nivolumab: Given IV
    id
    OG000
    title
    Treatment (Nivolumab, Paclitaxel, Carboplatin)
param Type
NUMBER
population Description
number of patients with Major response (Major or complete) was 72.73% (24/33) with a 95% Confidence Interval of 54.2% to 86.1%.
reporting Status
POSTED
time Frame
Up to 26 months
title
Number of Patients Who Achieved Major Pathologic Response (Defined as 10% or Less Residual Viable Tumor)
type
SECONDARY
unit Of Measure
percentage of major response

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice